MicroPort Attends AAOS

From March 24 to March 28, American Academy of Orthopedic Surgeons ("AAOS") was held in Las Vegas. The Academy, founded in 1933, is the preeminent provider of musculoskeletal education to orthopedic surgeons and others in the world. MicroPort attended the meeting to promote our brand image.
45th Annual Meeting of JSRA

The 45th Annual meeting of the Japanese Society for Replacement Arthroplasty (“JSRA”) was held in Fukuoka on February 27 and February 28. Many surgeons came to visit the MicroPort Orthopedics booth and we received about 120 questions and requests during the two-day meeting.
Shanghai MicroPort Orthopedics Attends CHS Annual Congress

On March 7, Shanghai MicroPort Orthopedics attended at one of the largest Chinese hip society meetings, the 3rd Chinese Hip Society ("CHS") Annual Congress in Chongqing, China. MicroPort Orthopedics Shanghai held a SuperPath™ satellite meeting during the congress, which was focused on “How Micro-Posterior Approach Supports Fast Recovery Total Hip Arthroplasty ("THA").” This is the first SuperPath™ meeting presented by Chinese surgeons. Over 200 surgeons attended the satellite meeting. It was chaired by the CHS Chairman Dr. Xianlong Zhang, Dr. Yunsu Chen, the Youth Committee Member of Chinese Orthopedic Society, and Dr. Bing Xia, Chief Surgeon of Zhejiang Province Hospital, delivered speeches at the satellite meeting, explaining both in theory and in practice how SuperPath™ works as a better alternative approach in MIS THA. In the panel discussion, the two renowned THA experts and the Chairman answered questions from the audience, regarding the advantages of SuperPath™ technique compared to classic posterior approach, patient selection, and precautions of the procedure. Dr. Michael Huo from the US commented that SuperPath™ is an effective MIS THA approach. Compared to DAA, SuperPath™ features shorter learning curve and less risk of nerve damage, and it doesn’t need additional supporting equipment.

200 SuperPath™ surgical technique DVDs were handed out at the meeting, and 38 surgeons left their contact details to schedule further discussions with us in their hospitals. This meeting has been a great success and a milestone of SuperPath™ campaign in China. With the support of CHS, we have delivered a clear message to the market that we are committed to continuously providing safe and effective MIS solutions for joint reconstruction surgeries to further improve clinical outcomes and patient satisfaction.
Futago™ Lumbar & Thoracic Fusion Device
Awarded CFDA Registration Certificate

Shanghai MicroPort Orthopedics recently gained the registration certificate from China Food and Drug Administration ("CFDA") for its in-house-developed Futago™ Lumbar & Thoracic Fusion Device ("Futago™"). Futago™ received CE Mark approval in 2011.

Futago™ is consisted of a fusion device and a mark. The fusion device is made of Polyetheretherketone ("PEEK") and the mark is made of titanium alloy. Futago™ is implanted in posterior approach, compatible with Spinal Posterior Fixation System, and indicated for lumbar or thoracic interbody fusion, including degenerative discopathy, lumbar pseudarthrosis and degenerative or isthmic with grade 1 residual displacement after reduction. Futago™ features patented teeth design, biocompatible PEEK material, secure implant placement, optimum graft area for bone ingrowth and special anatomic design which makes the implant easy to insert.

MicroPort Orthopedics Shanghai started to design and develop Futago™ in 2009. The first clinical implantation of Futago™ was completed in July 2010, in which a total of 70 patients were implanted the device and the fusion rate achieved 100%, proving its safety and efficacy.
MicroPort Attends CIT 2015

MicroPort recently attended China Interventional Therapeutics ("CIT"), the biggest International academic congress in the field of interventional cardiology in China, which was held in Beijing from March 19 to March 22. During the event, MicroPort organized several satellite symposiums to promote its in-house developed third-generation drug-eluting stent ("DES") Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk") and Firebird2™ Rapamycin-Eluting Coronary CoCr Stent ("Firebird2”).

On March 21, MicroPort hosted a satellite symposium themed "Conquest of Challenges, Confidence Based Evidence – Update on TARGET Clinical Program." Cardiologist Runlin Gao of Fuwai Hospital, Professor Weifeng Shen of Shanghai Ruijin Hospital, Professor Yundai Chen of Chinese PLA General Hospital, and Dr. Martin B. Leon, Director of Center for Interventional Vascular Therapy of Columbia University, chairman of TCT and principal co-investigator of TARGET trial, were invited to chair the symposium. After introducing Firehawk®’s features, Dr. Martin B. Leon commented that Firehawk® is a safe, effective, and easy-to-use DES. Cardiologist Runlin Gao then presented the latest data of TARGET trial – TARGET II three-year study data show that the rate of Target Lesion Failure ("TLF") is as low as 6.5%, proving Firehawk®'s efficacy and safety in treatment of complex cardiovascular diseases.

Firehawk® gained CE Mark approval from the European Notified Body on January 23, 2015. On the basis of existing research, MicroPort has launched a large-scale, randomized trial - TARGET All Comer - in Europe, to further study Firehawk®'s clinical performance. William Wijns, TARGET All Comer's principal investigator, introduced the theoretical foundations and design scheme of TARGET All Comer to people in attendance.

In another satellite symposium held on March 21, MicroPort shared "Ten Years' Journey of Firebird Series" with participants. Yan li, Deputy Director of Cardiology Department of Xijing Hospital, spoke highly of Firebird2™’s performance in treatment of PCI in diabetes. Three international experts later presented Firebird2™’s performance in treatment of complex PCI, proving its excellent efficiency and safety.
FOXTROT™ NC PTCA Balloon Catheter Gains FDA Approval

MicroPort recently received 510k approval from US Food and Drug Administration ("FDA") for its in-housed developed FOXTROT™ NC PTCA Balloon Catheter, which is MicroPort’s first coronary device that gained FDA approval.

FOXTROT™ NC PTCA Balloon Catheter received its CE mark in September 2013. It was permitted to enter into the Japanese market by Japan’s Ministry of Health Labour and Welfare ("MHLW") in September 2005.

FOXTROT™ NC PTCA Balloon Catheter is a sterile, single-use, rapid exchange percutaneous transluminal coronary angioplasty catheter. The design is an integrated shaft system with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures. Two radiopaque markers aid in positioning the balloon catheter under fluoroscopy during the procedure. The distal portion of the shaft is coated with a hydrophilic coating to provide lubrication.

FOXTROT™ NC PTCA Balloon Catheter is indicated for the balloon catheter dilatation of the stenotic portion of a native coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion, as well as the post-delivery expansion of balloon expandable stents.
MicroPort Endovascular Attends LINC Asia-Pacific 2015

LINC Asia-Pacific 2015, an interdisciplinary live course designed to provide a global platform for colleagues of different specialties who are performing endovascular interventions, was held in Hong Kong from March 9 to March 11. MicroPort Endovascular was present with a booth, which attracted a lot of attention.

On March 11, we broadcasted a surgery in which Castor Thoracic Branch Stent-Graft System was used to treat thoracic aortic dissection and released six-month follow-up data of Castor.
MicroPort Endovascular Completes
First Application of Reewarm™ PTX Drug Balloon Dilation Catheter

MicroPort Endovascular recently successfully completed its first clinical application of Reewarm™ PTX Drug Balloon Dilation Catheter ("Reewarm™ PTX") in the middle segment of superficial artery. The Reewarm™ PTX clinical trial is a prospective, multi-center, single blind, randomized, controlled study, comparing drug coated balloon ("DCB") versus standard balloon angioplasty for the treatment of femoropopliteal arteries, which is expected to enroll 200 patients (1:1) in 11 centers in China.

Reewarm™ PTX is an in-housed developed device of MicroPort Endovascular, designed for the treatment of peripheral arterial disease ("PAD") in the superficial femoral artery and popliteal artery. DCB technologies represent the latest development in the field of endovascular treatment of PAD, which combines balloon angioplasty and drug coating technology. Use of DCB and avoidance of stent implantation does not limit future treatment options, an important consideration given the chronic and progressive nature of PAD. Moreover, with no polymer carrier, DCB reduces the occurrence of chronic inflammation and late thrombosis.

MicroPort Endovascular's Reewarm™ PTX features unique coating formula and technology, which ensures that the drug is evenly coated on the balloon surface. The coating is composed of antiproliferative lipophilic paclitaxel with 3μg/mm² in dose and hydrophilic carrier. Its special drug coating structure and hydrophilic nano-scale coating design provides precise drug release, which guarantees adequate drug supply in lesions and reduces drug residues in blood and other non-target lesions, so as to lower the incidence of side effect.

"Reewarm™ PTX provides patients with an additional option to treat PAD. It will also help enhance our competitiveness in the field of endovascular treatment," said Zhenghua Miao, President of MicroPort Endovascular.
MicroPort EP Promotes Products in Interventional Cardiology Symposium

On March 16, the First Hospital of Hebei Medical University hosted an interventional cardiology symposium in Shijiazhuang of Hebei Province. MicroPort EP attended the event and promoted our products.

FOXTROT NC Offers More Specifications

On March 18, MicroPort recently gained approval from European Third-party Certification Body DEKRA to add 44 specifications to the CE mark of FOXTROT NC PTCA Balloon Catheter. With 60 specifications, FOXTROT NC will offer more options to surgeons and patients, which will increase its competitiveness in the European market.
MicroPort Orthopedics Launches Community Service

On March 1, Shanghai MicroPort Orthopedics went to a nursing home in Dujiangyan of Chengdu Province, to bring love and care to old people living there. Lijun Huang, the sales manager for Fujian Province, who has been an orthopedic surgeon for many years, educated the elders about the causes of fracture and how to prevent osteoporosis. He also answered questions regarding bone health. Afterwards, we read a poem and sang a song for the residents to celebrate the just past Lantern Festival, a traditional Chinese festival for family get-together. We gave them small gifts and two umbrella stands to show our love for them.
Product Training

On March 1, DongGuan Kewei Medical Co invited a director of Anesthesiology Department with Sichuan University Hospital, to carry out training on cardiopulmonary bypass application. The Medical Affairs Department also organized a training program on congenital heart disease, occluder and occluder delivery system to enhance salespersons’ understanding in our products.

Distributor Training

On March 21, MicroPort Endovascular organized product training for our distributors in Guangzhou, Guangdong Province, focused on operation methods of Hercules™ Delivery System and Aegis™ Bifurcated Stent-graft System.
For more information, please contact:

Hongbin Sun
Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600
Email: ir@microport.com

Xun You
Board Secretary
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600
Email: ir@microport.com